Impact of discontinuation of initial protease inhibitor therapy on further virological response in a cohort of human immunodeficiency virus-infected patients

Clinical Infectious Diseases

Volumn 34, Issue 2, 2002, Pages 239-247

  Le Moing, Vincent ^a   Chêne, Geneviève ^b   Leport, Catherine ^a   Lewden, Charlotte ^b   Duran, Ségolène ^c   Garré, Michel ^d   Masquelier, Bernard ^e   Dupon, Michel ^f   Raffi, François ^g   Leport, C ^h   Raffi, F ^h   Chene G ^h   Salamon, R ^h   Moatti, J P ^h   Pierret, J ^h   Brun Vezinet F ^h   Fleury, H ^h   Peytavin, G ^h   Costagliola, D ^h   Dellamonica, P ^h   Katlama, C ^h   Meyer, L ^h   Morin, M ^h   Sicard, D ^h   Sobel, A ^h   Vincent Ballereau, F ^h   Dupon, M ^h   Le Moing, V ^h   Marchou, B ^h   May, T ^h,h   Morlat, P ^h   Waldner Combernoux, A ^h   Bach, M A ^h   Bourdillon, F ^h   Delfraissy, J F ^h   Dormont, J ^h   Lacut, J Y ^h   Souteyrand, Y ^h   Vilde J L ^h   Schmit, J L ^h   Pichard, E ^h   Faller, J P ^h   Estavoyer, J M ^h   Laurent, P ^h   Vuitton, P ^h   Beylot, J ^h   Le Bras, M ^h   Ragnaud, J M ^h   Granier, P ^h   Garre M ^h   Bazin, C ^h   Veyssier, P ^h   Devidas, A ^h   Pottier, H ^h   Perronne, C ^h   Lagarde, P ^h   Ceccaldi, J ^h   Peyramond, D ^h   Allard, C ^h   Reynes, J ^h   Cassuto, J P ^h   Arsac, P ^h   Bouvet, E ^h   Bricaire, F ^h   Caulin, C ^h   Frottier, J ^h   Herson, S ^h   Imbert, J C ^h   Malkin, J E ^h   Rozenbaum, W ^h   Becq Giraudon, B ^h   Remy G ^h   Michelet, C ^h   Lucht, F ^h   Roue R ^h   Lang, J M ^h   De Jaureguiberry, J P ^h   Massip, P ^h   Choutet, P ^h   more..

^a BICHAT HOSPITAL   (France)

^b Institut National pour la Santé et la Recherche Medicale U 330   (France)

^c Institut Nationale de Santé   (France)

^d SERVICE DE RHUMATOLOGIE   (France)

^e Lab Virol   (France)

^f HÔPITAL PELLEGRIN   (France)

^g HÔTEL DIEU   (France)

^h NONE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; VIRUS RNA;

ADULT; ARTICLE; CLINICAL PRACTICE; CRYSTALLURIA; DRUG RESPONSE; DRUG TOLERABILITY; DRUG USE; FEMALE; FOLLOW UP; GLUCOSE INTOLERANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; REGRESSION ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; FRANCE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; PROSPECTIVE STUDIES; SAQUINAVIR; TREATMENT FAILURE; TREATMENT REFUSAL;

EID: 0037079912     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/324354     Document Type: Article

References (28)

1. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
2. Analysis of the discontinuation of protease inhibitor in routine clinical practice
3. Incidence of discontinuation of highly active antiretroviral combination therapy and its determinants
4. Les arrêts pour intolérance des traitements par inhibiteurs de la protéase du VIH-1
5. Outcome and predictors of failure of highly active antiretroviral therapy: One-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons
6. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy regimen in a cohort of antiretroviral naive patients
7. Incidence of adverse reactions in HIV patients treated with protease inhibitors: A cohort study
8. Long-term outcome and treatment modifications in a prospective cohort of human immunodeficiency virus type 1-infected patients on triple-drug therapy
9. Reasons for modification and discontinuation of antiretrovirals: Results from a single treatment centre
10. Virologic and regimen termination surrogate endpoints in AIDS clinical trials
11. Description et traduction de l'échelle d'autoévaluation
12. Definition of virological response and the type of assay used for quantification of viral load may influence the proportion of responders to antiretroviral therapy
13. Distinguishing efficacy, individual effectiveness, and population effectiveness of therapies
14. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions
15. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor
16. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine
17. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 counts of 200 per cubic millimeter or less
18. Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
19. Antiviral effect of double and triple drug combinations amongst HIV-infected adults: Lessons from the implementation of viral-load driven antiretroviral therapy
20. Risk factors for ritonavir intolerance and outcome after change to indinavir
21. Outcome of a second-line protease inhibitor-containing regimen in patients failing or intolerant of a first highly active antiretroviral therapy
22. Treatment adherence to HIV medications
23. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy
24. Self-reported symptoms after initiation of protease inhibitor in HIV-infected patients and their impact on adherence to HAART
25. Adherence to HAART in French HIV-infected injecting drug users: The contribution of buprenorphine drug maintenance treatment
26. Virological response to protease inhibitor in an HIV clinic cohort
27. Predictors of virological rebound after early virological response in a cohort of HIV-1-infected patients initiating a protease inhibitor-containing regimen
28. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy